OncoSec Medical Appoints New Executive Director of Research and Development

Publishing & Media

Share Tweet

OncoSec Medical Appoints New Executive Director of Research and Development

OncoSec Medical Inc.’s (OTCQB: ONCS) share volume was strong Apr. 21 with 2,910,820 shares changing hands.

The surge in stock volume is being spurred in part by the San Diego-based bio-tech company’s announcement that it has appointed Jean S. Campbell, Ph.D. as Executive Director of Research and Development, a newly created position.  According to OncoSec Medical, Campbell, an associate professor in the Department of Pathology in the School of Medicine at the University of Washington, Seattle, will leverage her considerable expertise in cancer biology and signal transduction to investigate mechanisms of immune tolerance in cancer.

"Dr. Campbell brings to the OncoSec team an extensive research background and a deep understanding of cancer biology and tumor progression," said OncoSec’s President and CEO Punit Dhillon.

 On Apr. 21, ONCS’s share price closed at 78 cents, up 6 cents from the previous day’s close of 72 cents a share.

Sign up today for timely and hot stock alerts here, or by cutting and pasting the following link in your Web browser:



Plandai Biotechnology to Begin Human Bioavailability Study

In other news, Plandai Biotechnology Inc. (OTCQB: PLPL), a  company that develops heath products from cannabis plant extracts, announced that it has received approval from the Ethics Committee at North West University in Potchefstroom, South Africa to commence a human clinical trial to test the oral bioavailability of its Phytofare(TM) Catechin Complex.

Phytofare(TM) is the trade name for live plant material extracts that have undergone the Company's proprietary hydrodynamic sheering process to rearrange the isomeric configuration of the molecules into a format biocompatible with human tissues.

The study will compare the oral bioavailability -- meaning the level of catechin absorption into the blood stream - of Phytofare(TM) compared with green tea extracts that have not been processed as well as Phytofare(TM) that has subsequently been further entrapped in Pheroid(R). The Company anticipates that the trial will demonstrate that Phytofare(TM) and Phytofare(TM) entrapped in Pheroid(R) have materially significant superior bioavailability, which should provide the ability to deliver a clinical level of plant nutrients as relatively low dosages. Plandai believes that this will unlock the health potential of not only green tea but also other phytonutrients which suffer from low natural bioavailability.

According to the timeline provided by the University, the recruitment of the participants is scheduled to start on the 14th of April. The start date of the first leg, where the bioavailability of the comparator will be determined, is scheduled for the 11th of May. Final results from all three legs of the trial should be available in July 2014. North West University, located in Potchefstroom, South Africa, is considered one of the finest research facilities on the continent.

On Apr. 21,   the share value of PLPL closed at 79 cents, up 16 cents from  the previous day’s close of 63 cents, on volume of 989,477 shares.

Sign up today for timely and hot stock alerts here, or by cutting and pasting the following link in your Web browser:


Provectus Pharmaceuticals’ Phase II Melanoma Drug Study Is Completed

Meanwhile, Provectus Pharmaceuticals Inc.’s (OTC: PVCT) share price on Apr. 21 closed at $2.43, up 11 cents from the share price of $2.32 cents the previous day.

The development-stage pharmaceutical company is developing medicines for oncology and dermatology applications. Provectus product line includes PV-10, a Phase II study completed drug candidate for metastatic melanoma, a Phase I study completed candidate for breast cancer, and a Phase I protocol expansion candidate for liver metastasis.

In addition it is conducting PH-10, a Phase IIc randomized study initiated drug candidate for the treatment of psoriasis, and Phase II study completed candidate for atopic dermatitis. It also develops PH-10 for the treatment of actinic keratosis and severe acne vulgaris.

Moreover, the company develops over-the-counter pharmaceuticals, including GloveAid, a hand cream with antiperspirant and antibacterial properties; Pure-ific line of products to prevent the spread of germs on skin; and Pure-Stick and Pure N Clear acne products.

Sign up today for timely and hot stock alerts here, or by cutting and pasting the following link in your Web browser:


Titan Medical Inc. Files Prospectus Supplement

Finally, Titan Medical Inc.’s (OTCQX: TITXF) stock volume soared Apr. 21, with 612,804 shares changing hands, significantly higher than its three-month average volume of 488,500 shares.

The uptick in volume could be related the Canadian robotic surgical company’s recent announcement that it has filed a prospectus supplement.

Here’s an excerpt from the press release:

The company's short form base shelf prospectus dated Oct. 15, 2012, regarding its previously announced public offering of units of the Company ("Units"). Each Unit consists of one common share ("Share") of the Company and one Share purchase warrant ("Warrant"). Each Warrant entitles the holder thereof to acquire one Share at a price of $2.75 for a period of 36 months following the Closing Date (as defined below).

"Dundee Securities Ltd. (the "Agent") has agreed to sell, on a best efforts agency basis and, pursuant to the terms and conditions of an agency agreement dated April 10, 2014 between the Company and the Agent (the "Agency Agreement"), 10,611,469 Units at a price of $2.10 per Unit (the "Offering") for total gross proceeds of $22,284,085. The Agent has been granted the option to offer for sale up to an additional 15% of the Units issued under the Offering, exercisable in whole or in part on the Closing Date or at any time up to 30 days following the Closing Date. BayFront Capital Partners Ltd. is acting as a selling group member in connection with the Offering.

The Offering is scheduled to close on or about Apr. 23, 2014 (the "Closing Date"). The Offering is subject to a number of conditions, including, without limitation, receipt of all regulatory approvals.

The Securities offered have not been registered under the U.S. Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the Securities in any jurisdiction in which such offer, solicitation or sale would be unlawful.”

On Apr. 21, TITXF’s share price closed at $1.91, down 7 cents from the previous day’s close of $1.98 a share.

Sign up today for timely and hot stock alerts here, or by cutting and pasting the following link in your Web browser:




Pennypickalerts.com issues momentum alerts on stocks that can provide gains to day traders.

Pennypickalerts.com provides members with timely information and exclusive alerts on cheap and under-valued stocks in the United States with the potential to deliver gains of 100% - 200% or more.

Pennypickalerts.com monitors and scans the markets for stock related signals as well as any external factors that might bring trading opportunities. Through a vast network of IR professionals Pennypickalerts.com is often in the know of several large investor awareness campaigns being deployed.

Timing is everything when trading Penny Stocks. Gain an Edge by joining the Pennypickalerts.com newsletter and receiving alerts from a Pro-Active team of researchers. Pennypickalerts.com believes traders should have a chance at successfully trading penny stocks and invites traders and investors to be part of the Free VIP membership.

Simply sign up for free and start receiving exclusive alerts.

Subscribe Here: http://www.pennypickalerts.com


Pennypickalerts.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always own due diligence with any potential investment.